<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39407293</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1742-4933</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Immunity &amp; ageing : I &amp; A</Title><ISOAbbreviation>Immun Ageing</ISOAbbreviation></Journal><ArticleTitle>Health characteristics associated with persistence of SARS-CoV-2 antibody responses after repeated vaccinations in older persons over time: the Doetinchem cohort study.</ArticleTitle><Pagination><StartPage>68</StartPage><MedlinePgn>68</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">68</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12979-024-00476-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Older persons elicit heterogeneous antibody responses to vaccinations that generally are lower than those in younger, healthier individuals. As older age and certain comorbidities can influence these responses we aimed to identify health-related variables associated with antibody responses after repeated SARS-CoV-2 vaccinations and their persistence thereafter in SARS-CoV-2 infection-naïve and previously infected older persons.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">In a large longitudinal study of older persons of the general population 50 years and over, a sub-cohort of the longitudinal Doetinchem cohort study (n = 1374), we measured IgG antibody concentrations in serum to SARS-CoV-2 Spike protein (S1) and Nucleoprotein (N). Samples were taken following primary vaccination with BNT162b2 or AZD1222, pre- and post-vaccination with a third and fourth BNT162b2 or mRNA-1273 (Wuhan), and up to a year after a fifth BNT162b2 bivalent (Wuhan/Omicron BA.1) vaccine. Associations between persistence of antibody concentrations over time and age, sex, health characteristics including cardiometabolic and inflammatory diseases as well as a frailty index were tested using univariable and multivariable models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The booster doses substantially increased anti-SARS-CoV-2 Spike S1 (S1) antibody concentrations in older persons against both the Wuhan and Omicron strains. Older age was associated with decreased antibody persistence both after the primary vaccination series and up to 1 year after the fifth vaccine dose. In infection-naïve persons the presence of inflammatory diseases was associated with an increased antibody response to the third vaccine dose (Beta = 1.53) but was also associated with reduced persistence over the 12 months following the fifth (bivalent) vaccine dose (Beta = -1.7). The presence of cardiometabolic disease was associated with reduced antibody persistence following the primary vaccination series (Beta = -1.11), but this was no longer observed after bivalent vaccination.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Although older persons with comorbidities such as inflammatory and cardiometabolic diseases responded well to SARS-CoV-2 booster vaccinations, they showed a reduced persistence of these responses. This might indicate that especially these more vulnerable older persons could benefit from repeated booster vaccinations.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kuijpers</LastName><ForeName>Yunus</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Centre for Prevention, Lifestyle and Health, National Institute for Public Health and the Environment (RIVM), Bilthoven, 3721 MA, The Netherlands. Yunus.Kuijpers@rivm.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaczorowska</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment (RIVM), Bilthoven, 3721 MA, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Picavet</LastName><ForeName>H Susan J</ForeName><Initials>HSJ</Initials><AffiliationInfo><Affiliation>Centre for Prevention, Lifestyle and Health, National Institute for Public Health and the Environment (RIVM), Bilthoven, 3721 MA, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Zeeuw-Brouwer</LastName><ForeName>Mary-Lène</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment (RIVM), Bilthoven, 3721 MA, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuijer</LastName><ForeName>Marjan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment (RIVM), Bilthoven, 3721 MA, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slits</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment (RIVM), Bilthoven, 3721 MA, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gijsbers</LastName><ForeName>Esther</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment (RIVM), Bilthoven, 3721 MA, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rutkens</LastName><ForeName>Ryanne</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment (RIVM), Bilthoven, 3721 MA, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Rond</LastName><ForeName>Lia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment (RIVM), Bilthoven, 3721 MA, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verschuren</LastName><ForeName>W M Monique</ForeName><Initials>WMM</Initials><AffiliationInfo><Affiliation>Centre for Prevention, Lifestyle and Health, National Institute for Public Health and the Environment (RIVM), Bilthoven, 3721 MA, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Utrecht, 3508 TC, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buisman</LastName><ForeName>Anne-Marie</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment (RIVM), Bilthoven, 3721 MA, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Immun Ageing</MedlineTA><NlmUniqueID>101235427</NlmUniqueID><ISSNLinking>1742-4933</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Ageing</Keyword><Keyword MajorTopicYN="N">Antibody persistence</Keyword><Keyword MajorTopicYN="N">Antibody responses</Keyword><Keyword MajorTopicYN="N">COVID-19 vaccination</Keyword><Keyword MajorTopicYN="N">Cardiometabolic diseases</Keyword><Keyword MajorTopicYN="N">Comorbidities</Keyword><Keyword MajorTopicYN="N">Frailty</Keyword><Keyword MajorTopicYN="N">Inflammatory diseases</Keyword><Keyword MajorTopicYN="N">Omicron</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>0</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>23</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39407293</ArticleId><ArticleId IdType="pmc">PMC11476400</ArticleId><ArticleId IdType="doi">10.1186/s12979-024-00476-7</ArticleId><ArticleId IdType="pii">10.1186/s12979-024-00476-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Crooke SN, Ovsyannikova IG, Poland GA, Kennedy RB. Immunosenescence and human vaccine immune responses. Immun Ageing 2019 Sept 13;16(1). 10.1186/s12979-019-0164-9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6743147</ArticleId><ArticleId IdType="pubmed">31528180</ArticleId></ArticleIdList></Reference><Reference><Citation>Goronzy JJ, Weyand CM. Understanding immunosenescence to improve responses to vaccines. Nat Immunol. 2013;14(5):428–36. 10.1038/ni.2588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4183346</ArticleId><ArticleId IdType="pubmed">23598398</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira B, Xu X-N, Akbar AN. Targeting inflammation and immunosenescence to improve vaccine responses in the elderly. Front Immunol. 2020;11. 10.3389/fimmu.2020.583019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7592394</ArticleId><ArticleId IdType="pubmed">33178213</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen JC, Toapanta FR, Chen W, Tennant SM. Understanding immunosenescence and its impact on vaccination of older adults. Vaccine. 2020;38(52):8264–72. 10.1016/j.vaccine.2020.11.002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7719605</ArticleId><ArticleId IdType="pubmed">33229108</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Klein SL, Garibaldi BT, Li H, Wu C, Osevala NM, et al. Aging in COVID-19: vulnerability, immunity and intervention. Ageing Res Rev. 2021;65:101205. 10.1016/j.arr.2020.101205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7604159</ArticleId><ArticleId IdType="pubmed">33137510</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotshild V, Hirsh-Raccah B, Miskin I, Muszkat M, Matok I. Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis. Sci Rep. 2021;11(1). 10.1038/s41598-021-02321-z.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8611039</ArticleId><ArticleId IdType="pubmed">34815503</ArticleId></ArticleIdList></Reference><Reference><Citation>Speletas M, Voulgaridi I, Bogogiannidou Z, Sarrou S, Kyritsi MA, Theodoridou A, et al. Dynamics of anti-SARS-cov-2 IGA and IGG responses and their protective effect against fatal disease after booster covid-19 vaccination. Vaccines. 2023;12(1):12. 10.3390/vaccines12010012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10819547</ArticleId><ArticleId IdType="pubmed">38276671</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Hoogen LL, Boer M, Postema A, de Rond L, de Zeeuw-Brouwer M, Pronk I et al. Reduced antibody acquisition with increasing age following vaccination with BNT162b2: Results from two longitudinal cohort studies in the Netherlands. Vaccines. 2022 Sept 6;10(9):1480. 10.3390/vaccines10091480</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9504637</ArticleId><ArticleId IdType="pubmed">36146557</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuijpers Y, Picavet HS, de Rond L, de Zeeuw-Brouwer M, Rutkens R, Gijsbers E, et al. Potential determinants of antibody responses after vaccination against SARS-COV-2 in older persons: the Doetinchem Cohort Study. Immun Ageing. 2023;20(1). 10.1186/s12979-023-00382-4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10599057</ArticleId><ArticleId IdType="pubmed">37880758</ArticleId></ArticleIdList></Reference><Reference><Citation>Verschuren W, Blokstra A, Picavet H, Smit H. Cohort profile: the doetinchem cohort study. Int J Epidemiol. 2008;37(6):1236–41. 10.1093/ije/dym292.</Citation><ArticleIdList><ArticleId IdType="pubmed">18238821</ArticleId></ArticleIdList></Reference><Reference><Citation>Picavet HS, Blokstra A, Spijkerman AM, Verschuren WM. Cohort profile update: the Doetinchem Cohort Study 1987–2017: Lifestyle, health and chronic diseases in a life course and ageing perspective. Int J Epidemiol. 2017;46(6). 10.1093/ije/dyx103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837330</ArticleId><ArticleId IdType="pubmed">29040549</ArticleId></ArticleIdList></Reference><Reference><Citation>den Hartog G, Schepp RM, Kuijer M, GeurtsvanKessel C, van Beek J, Rots N, et al. SARS-COV-2–specific antibody detection for seroepidemiology: a multiplex analysis approach accounting for accurate seroprevalence. J Infect Dis. 2020;222(9):1452–61. 10.1093/infdis/jiaa479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454740</ArticleId><ArticleId IdType="pubmed">32766833</ArticleId></ArticleIdList></Reference><Reference><Citation>Samson LD, Boots AM, Verschuren WMM, Picavet HS, Engelfriet P, Buisman A-M. Frailty is associated with elevated CRP trajectories and higher numbers of neutrophils and monocytes. Exp Gerontol. 2019;125:110674. 10.1016/j.exger.2019.110674.</Citation><ArticleIdList><ArticleId IdType="pubmed">31336145</ArticleId></ArticleIdList></Reference><Reference><Citation>Karachaliou M, Moncunill G, Espinosa A, Castaño-Vinyals G, Rubio R, Vidal M et al. SARS-COV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia. BMC Med 2022 Sept 16;20(1). 10.1186/s12916-022-02547-2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9479347</ArticleId><ArticleId IdType="pubmed">36109713</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia H, Huang W, Liu C, Tang S, Zhang J, Chen C, et al. Immunosenescence is a therapeutic target for frailty in older adults: a narrative review. Annals Translational Med. 2022;10(20):1142–1142. 10.21037/atm-22-4405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9652526</ArticleId><ArticleId IdType="pubmed">36388790</ArticleId></ArticleIdList></Reference><Reference><Citation>Wildes TJ, Grippin A, Fasanya H, Dyson KA, Brantly M. Effect of atorvastatin on humoral immune response to 23-valent pneumococcal polysaccharide vaccination in healthy volunteers: the StatVax randomized clinical trial. Vaccine. 2019;37(10):1313–24. 10.1016/j.vaccine.2019.01.023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6379110</ArticleId><ArticleId IdType="pubmed">30686636</ArticleId></ArticleIdList></Reference><Reference><Citation>Garner-Spitzer E, Wagner A, Gudipati V, Schoetta A-M, Orola-Taus M, Kundi M, et al. Lower magnitude and faster waning of antibody responses to SARS-COV-2 vaccination in anti-tnf-α-treated IBD patients are linked to lack of activation and expansion of ctfh1 cells and impaired B memory cell formation. eBioMedicine. 2023;96:104788. 10.1016/j.ebiom.2023.104788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10485594</ArticleId><ArticleId IdType="pubmed">37672867</ArticleId></ArticleIdList></Reference><Reference><Citation>van Sleen Y, et al. Humoral SARS–CoV-2 vaccine responses in patients with giant cell arteritis and polymyalgia rheumatica: Decay after primary vaccination and effects of the booster. Arthritis Care Res. 2023;76(1):105–10. 10.1002/acr.25173.</Citation><ArticleIdList><ArticleId IdType="pubmed">37332051</ArticleId></ArticleIdList></Reference><Reference><Citation>Abhishek A, Peckham N, Pade C, Gibbons JM, Cureton L, Francis A, et al. Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (vroom study): a randomised, open label, superiority trial. Lancet Rheumatol. 2024;6(2). 10.1016/s2665-9913(23)00298-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">38267107</ArticleId></ArticleIdList></Reference><Reference><Citation>Vikström L, Fjällström P, Gwon Y-D, Sheward DJ, Wigren-Byström J, Evander M, et al. Vaccine-induced correlate of protection against fatal COVID-19 in older and frail adults during waves of neutralization-resistant variants of concern: an observational study. Lancet Reg Health - Europe. 2023;30:100646. 10.1016/j.lanepe.2023.100646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10163377</ArticleId><ArticleId IdType="pubmed">37363799</ArticleId></ArticleIdList></Reference><Reference><Citation>da Fernandes M, Vasconcelos GS, de Melo AC, Matsui TC, Caetano LF, de Carvalho Araújo FM, et al. Influence of age, gender, previous SARS-COV-2 infection, and pre-existing diseases in antibody response after COVID-19 vaccination: a review. Mol Immunol. 2023;156:148–55. 10.1016/j.molimm.2023.03.007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9998295</ArticleId><ArticleId IdType="pubmed">36921489</ArticleId></ArticleIdList></Reference><Reference><Citation>Trevisan C, Raparelli V, Malara A, Abbatecola AM, Noale M, Palmieri A, Fedele G, Di Lonardo A, Leone P, Schiavoni I, Stefanelli P, Volpato S, Antonelli Incalzi R, Onder G. GeroCovid Vax working group. Sex differences in the efficacy and safety of SARS-CoV-2 vaccination in residents of long-term care facilities: insights from the GeroCovid Vax study. Intern Emerg Med. 2023;18(5):1337–47. 10.1007/s11739-023-03283-y.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10148701</ArticleId><ArticleId IdType="pubmed">37120663</ArticleId></ArticleIdList></Reference><Reference><Citation>Shapiro JR, et al. Association of Frailty, age, and biological sex with severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine–induced immunity in older adults. Clin Infect Dis. 2022;75(Supplement1). 10.1093/cid/ciac397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9376280</ArticleId><ArticleId IdType="pubmed">35607747</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho Á, Henriques AR, Queirós P, Rodrigues J, Mendonça N, Rodrigues AM, et al. Persistence of IGG COVID-19 antibodies: a longitudinal analysis. Front Public Health. 2023;10. 10.3389/fpubh.2022.1069898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9872107</ArticleId><ArticleId IdType="pubmed">36703818</ArticleId></ArticleIdList></Reference><Reference><Citation>de Oliveira MI, Aciole MR, Neves PA, Silva VP, Silva MP, de Lorena VM, et al. A stronger antibody response in increased disease severity of SARS-COV-2. BMC Infect Dis. 2024;24(1). 10.1186/s12879-023-08923-4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10762998</ArticleId><ArticleId IdType="pubmed">38166763</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen L, Brokstad KA, Bansal A, Zhou F, Bredholt G, Onyango TB, et al. Durable immune responses after BNT162B2 vaccination in home-dwelling old adults. Vaccine: X. 2023;13:100262. 10.1016/j.jvacx.2023.100262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9830931</ArticleId><ArticleId IdType="pubmed">36643855</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiolet T, Kherabi Y, MacDonald C-J, Ghosn J, Peiffer-Smadja N. Comparing covid-19 vaccines for their characteristics, efficacy and effectiveness against SARS-COV-2 and variants of concern: a narrative review. Clin Microbiol Infect. 2022;28(2):202–21. 10.1016/j.cmi.2021.10.005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8548286</ArticleId><ArticleId IdType="pubmed">34715347</ArticleId></ArticleIdList></Reference><Reference><Citation>Naaber P, Tserel L, Kangro K, Sepp E, Jürjenson V, Adamson A, et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health - Europe. 2021;10:100208. 10.1016/j.lanepe.2021.100208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8418937</ArticleId><ArticleId IdType="pubmed">34514454</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruel T, et al. Neutralising antibody responses to SARS-COV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: a community-based, prospective, longitudinal cohort study. eClinicalMedicine. 2022;51:101576. 10.1016/j.eclinm.2022.101576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307278</ArticleId><ArticleId IdType="pubmed">35891947</ArticleId></ArticleIdList></Reference><Reference><Citation>Fedele G, et al. A third dose of mrna COVID-19 vaccine significantly enhances anti–SARS-COV-2 spike IGG response in nursing home residents in Italy. J Am Med Dir Assoc. 2022;23(7):1114–5. 10.1016/j.jamda.2022.05.006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9108031</ArticleId><ArticleId IdType="pubmed">35661654</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeulin H, et al. Anti-spike IgG antibody kinetics following the second and third doses of BNT162b2 vaccine in nursing home residents. J Am Geriatr Soc. 2022;70(9):2552–60. 10.1111/jgs.17837.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115082</ArticleId><ArticleId IdType="pubmed">35484977</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto N, Sasaki A, Kadowaki T, Mitsuhashi T, Takao S, Yorifuji T. Longitudinal antibody dynamics after COVID-19 vaccine boosters based on prior infection status and booster doses. Sci Rep. 2024;14(1). 10.1038/s41598-024-55245-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10894855</ArticleId><ArticleId IdType="pubmed">38403650</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng SMS, Mok CKP, Li JKC, Chan KKP, Luk KS, Lee BHW et al. Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination. Virology Journal [Internet]. 2024;21(1). 10.1186/s12985-024-02335-9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10956325</ArticleId><ArticleId IdType="pubmed">38515117</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalkias S, McGhee N, Whatley JL, Essink B, Brosz A, Tomassini JE, et al. Interim report of the reactogenicity and immunogenicity of SARS-COV-2 XBB-containing vaccines. J Infect Dis. 2024. 10.1093/infdis/jiae067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11326827</ArticleId><ArticleId IdType="pubmed">38349280</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, et al. Persistence of immunogenicity after seven covid-19 vaccines given as third dose boosters following two doses of Chadox1 nCov-19 or BNT162B2 in the UK: three month analyses of the cov-boost trial. J Infect. 2022;84(6):795–813. 10.1016/j.jinf.2022.04.018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8993491</ArticleId><ArticleId IdType="pubmed">35405168</ArticleId></ArticleIdList></Reference><Reference><Citation>Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, et al. Homologous and heterologous covid-19 booster vaccinations. N Engl J Med. 2022;386(11):1046–57. 10.1056/nejmoa2116414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8820244</ArticleId><ArticleId IdType="pubmed">35081293</ArticleId></ArticleIdList></Reference><Reference><Citation>Boshuizen HC, et al. Non-response in a survey of cardiovascular risk factors in the Dutch population: determinants and resulting biases. Public Health. 2006;120(4):297–308. 10.1016/j.puhe.2005.09.008.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364384</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>